Compare SBET & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | DMRA |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2025 | 2020 |
| Metric | SBET | DMRA |
|---|---|---|
| Price | $5.49 | $21.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $18.71 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 7.3M | 300.4K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $105.19 | N/A |
| Revenue Next Year | $13.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $5.06 | $16.50 |
| 52 Week High | $49.52 | $28.76 |
| Indicator | SBET | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 31.57 |
| Support Level | N/A | $16.50 |
| Resistance Level | $8.20 | $26.66 |
| Average True Range (ATR) | 0.36 | 1.63 |
| MACD | -0.09 | -0.42 |
| Stochastic Oscillator | 27.81 | 12.21 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.